Tirzepatide (dual GLP-1/GIP agonist) and retatrutide (triple GLP-1/GIP/glucagon agonist) represent the two most potent weight loss agents in the GLP class. Retatrutide's Phase 2 data shows ~24% average weight loss vs tirzepatide's ~22.5% — but tirzepatide is FDA approved and has 3+ years of real-world data. Here is the complete head-to-head analysis.
Retatrutide edges ahead on average weight loss (~24% vs ~22.5%) due to its additional glucagon receptor agonism, but the gap is modest. Tirzepatide leads on regulatory status (FDA approved, 3+ years real-world data) and GI tolerability (lower nausea rate). For researchers prioritizing maximum weight loss potential, retatrutide is the more potent active ingredient. For those prioritizing established clinical evidence and long-term safety data, tirzepatide is the stronger choice.
The core difference between tirzepatide and retatrutide is one additional receptor target. Both compounds activate the GLP-1 receptor (appetite suppression, slowed gastric emptying) and the GIP receptor (enhanced insulin secretion, potential GI tolerability improvement). Retatrutide adds glucagon receptor agonism — a third mechanism that increases basal metabolic rate and fat oxidation independently of appetite suppression.
This triple action is why retatrutide produces greater average weight loss despite a similar starting mechanism to tirzepatide. The glucagon component drives energy expenditure even at rest, creating a caloric deficit that compounds over time. However, glucagon receptor activation also contributes to retatrutide's higher nausea rate (~47–58% vs ~33–45% for tirzepatide) and requires a longer titration period to manage GI tolerance.
Both compounds follow a similar trajectory in the early weeks, with divergence becoming significant after week 24 as retatrutide's glucagon component compounds. The following estimates are derived from Phase 2 and Phase 3 trial data and represent mean body weight reduction at each timepoint.
| Timepoint | Tirzepatide | Retatrutide | Notes |
|---|---|---|---|
| Week 4 | ~2–3% | ~2–3% | Both at starting doses |
| Week 12 | ~6–8% | ~6–9% | Dose escalation phase |
| Week 24 | ~12–14% | ~14–17% | Approaching maintenance dose; divergence begins |
| Week 36 | ~17–19% | ~19–22% | Glucagon component driving retatrutide ahead |
| Week 48 | ~20–22% | ~22–24% | Phase 2 primary endpoint for retatrutide |
| Week 72 | ~22.5% (SURMOUNT-1) | N/A (Phase 3 ongoing) | SURMOUNT-1 primary endpoint |
Note: Tirzepatide data from SURMOUNT-1 (Phase 3). Retatrutide data from NCT04881760 (Phase 2). Direct head-to-head trials are not yet available.
| Parameter | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor mechanism | GLP-1 + GIP (dual agonist) | GLP-1 + GIP + Glucagon (triple agonist) |
| Average weight loss (max dose) | ~22.5% (15 mg, SURMOUNT-1, 72 wks) | ~24% (24 mg, Phase 2, 48 wks) |
| Average weight loss (mid dose) | ~17–19% (10 mg, SURMOUNT-1) | ~17% (12 mg, Phase 2) |
| Titration period | ~20 weeks | ~24 weeks |
| Nausea rate (therapeutic dose) | 33–45% | 47–58% |
| GI discontinuation rate | ~5–8% | ~8–12% |
| Half-life | ~5 days (weekly injection) | ~6 days (weekly injection) |
| FDA approval status | Approved (Mounjaro/Zepbound) | Phase 3 trials (est. 2027–2028) |
| Cardiovascular outcome data | SURPASS-CVOT (ongoing analysis) | Not yet available |
| Long-term safety data | 3+ years real-world data | Phase 2 data only (48 weeks) |
| Blood sugar control | Strong (T2D approved, superior HbA1c ↓) | Strong (Phase 2 data) |
| Research-grade availability | Available (Purgo Labs) | Available (Purgo Labs) |
Retatrutide's ~24% weight loss figure comes from Phase 2 trials (n=338, 48 weeks). Tirzepatide's ~22.5% comes from Phase 3 SURMOUNT-1 (n=2,539, 72 weeks). Phase 3 trials typically show slightly lower efficacy than Phase 2 due to larger, more diverse populations. Retatrutide's Phase 3 TRIUMPH data (expected 2026) will provide a more direct comparison. Until then, the ~2 percentage point advantage for retatrutide should be interpreted with caution.
Based on available clinical trial data, yes — retatrutide produced ~24% mean body weight reduction at 48 weeks in Phase 2 trials (24 mg dose), compared to tirzepatide's ~22.5% (15 mg, SURMOUNT-1 at 72 weeks). The ~2 percentage point difference is smaller than retatrutide's advantage over semaglutide (~9 points), and Phase 3 data is needed to confirm whether this gap holds at scale. The difference is driven by retatrutide's additional glucagon receptor agonism, which increases energy expenditure on top of the shared GLP-1/GIP mechanism.
Tirzepatide is a dual GLP-1/GIP receptor agonist — it activates both the GLP-1 receptor (appetite suppression, slowed gastric emptying) and the GIP receptor (enhanced insulin secretion, potential GI tolerability improvement). Retatrutide is a triple agonist: it adds glucagon receptor activation on top of GLP-1 and GIP. Glucagon receptor agonism increases basal metabolic rate and fat oxidation, which is why retatrutide produces greater weight loss despite a similar GI tolerability profile to tirzepatide at matched doses.
Yes. Tirzepatide is FDA approved under two brand names: Mounjaro (type 2 diabetes, May 2022) and Zepbound (obesity, November 2023). Retatrutide is not yet FDA approved — it is in Phase 3 TRIUMPH trials with an estimated approval date of 2027–2028. For researchers evaluating regulatory status and long-term safety data, tirzepatide currently has a significantly more complete evidence base with 3+ years of real-world data.
Tirzepatide has a nausea rate of ~33–45% at therapeutic doses. Retatrutide has a higher nausea rate of ~47–58% at therapeutic doses, driven by its additional glucagon receptor activation and greater overall potency. GI discontinuation rates are also higher for retatrutide (~8–12% vs ~5–8% for tirzepatide). Both compounds require slow titration protocols to manage GI tolerance, but retatrutide's titration period is longer (~24 weeks vs ~20 weeks for tirzepatide) to accommodate the higher potency.
Both compounds produce strong blood sugar (HbA1c) reductions in type 2 diabetes patients. Tirzepatide has FDA approval for T2D and demonstrated superior HbA1c reduction vs semaglutide 1 mg in SURPASS-2 (−2.01% vs −1.86%). Retatrutide showed comparable HbA1c reductions in Phase 2 trials. However, tirzepatide has more extensive Phase 3 T2D data (SURPASS 1–5 program) and real-world evidence, giving it a stronger evidence base for blood sugar management at this time.
Both compounds show meaningful weight loss within 4–8 weeks of reaching therapeutic doses. Tirzepatide reaches its maximum dose (15 mg) after approximately 20 weeks of titration, with SURMOUNT-1 data showing ~22.5% weight loss at 72 weeks. Retatrutide reaches its maximum studied dose (24 mg) after approximately 24 weeks of titration, with Phase 2 data showing ~24% weight loss at 48 weeks. The weight loss trajectories diverge after week 24, with retatrutide pulling slightly ahead due to its glucagon-mediated energy expenditure component.
Research-grade tirzepatide and retatrutide are both available from Purgo Labs for research purposes. Purgo Labs provides pharmaceutical-grade compounds with third-party COAs from accredited US labs confirming ≥99% purity. Tirzepatide is also available as FDA-approved Mounjaro or Zepbound with a prescription. Retatrutide is not yet commercially available as a prescription drug — research-grade from verified suppliers is the only current source.
Purgo Labs provides pharmaceutical-grade tirzepatide and retatrutide with third-party COAs from accredited US labs confirming ≥99% purity. Use code HEALTH for 15% off your first order.
Shop Purgo LabsUse code HEALTH for 15% off · Research use only
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.